09:08 AM EDT, 07/08/2024 (MT Newswires) -- Outlook Therapeutics ( OTLK ) said Monday that the UK health regulator has granted marketing authorization for Lytenava, an ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration.

The European Commission recently granted marketing authorization for Lytenava for the same indication and the company said it expects a commercial drug launch in the EU and UK in the first quarter of 2025.

As part of a multi-year planning process, Outlook said it is collaborating with Cencora (COR) to support the commercial launch of Lytenava globally following regulatory approvals.